David Sheridan

8.9k total citations · 2 hit papers
36 papers, 2.9k citations indexed

About

David Sheridan is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, David Sheridan has authored 36 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hepatology, 25 papers in Epidemiology and 9 papers in Rheumatology. Recurrent topics in David Sheridan's work include Liver Disease Diagnosis and Treatment (25 papers), Hepatitis C virus research (22 papers) and Systemic Lupus Erythematosus Research (9 papers). David Sheridan is often cited by papers focused on Liver Disease Diagnosis and Treatment (25 papers), Hepatitis C virus research (22 papers) and Systemic Lupus Erythematosus Research (9 papers). David Sheridan collaborates with scholars based in United Kingdom, Australia and France. David Sheridan's co-authors include Margaret F. Bassendine, Jeremy Cobbold, Philip N. Newsome, Quentin M. Anstee, Emmanuel Tsochatzis, Michael Allison, M. Sasso, Peter Eddowes, Valérie Paradis and Pierre Bédossa and has published in prestigious journals such as Nature Genetics, Gastroenterology and Gut.

In The Last Decade

David Sheridan

33 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

2009 1.5k citations Vijayaprakash Suppiah, Max Moldovan et al. Nature Genetics profile →
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

2019 930 citations Peter Eddowes, M. Sasso et al. Gastroenterology profile →

Peers

Countries citing papers authored by David Sheridan

Since Specialization

Citations

This map shows the geographic impact of David Sheridan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sheridan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sheridan more than expected).

Fields of papers citing papers by David Sheridan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sheridan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sheridan. The network helps show where David Sheridan may publish in the future.

Co-authorship network of co-authors of David Sheridan

This figure shows the co-authorship network connecting the top 25 collaborators of David Sheridan. A scholar is included among the top collaborators of David Sheridan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sheridan. David Sheridan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD 2024 ·Diabetes Research and Clinical Practice ·Santo Colosimo, (unknown), Dimitrios A. Koutoukidis, Thomas Marjot, Garry D. Tan, D. J. Harman, Guruprasad P. Aithal, Pinelopi Manousou, Roberta Forlano, Richard Parker, David Sheridan, Philip N. Newsome, William Alazawi, Jeremy Cobbold, Jeremy Tomlinson	5
2	Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study 2024 ·BMJ Open ·(unknown), David G. Harman, Guruprasad P. Aithal, Pinelopi Manousou, Jeremy Cobbold, Richard Parker, David Sheridan, Philip N. Newsome, Fredrik Karpe, Matthew Neville, Wiebke Arlt, Alice Sitch, Márta Korbonits, Michael Biehl, William Alazawi, Jeremy Tomlinson	1
3	O19 The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK 2023 ·Oral Presentations ·Wenhao Li, David Sheridan, Stuart McPherson, William Alazawi	0
4	Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis 2022 ·Scientific Reports ·David Sheridan, Isaac Thom Shawa, E. Louise Thomas, Daniel J. Felmlee, Simon H. Bridge, Dermot Neely, Jeremy Cobbold, Elaine Holmes, Margaret F. Bassendine, Simon D. Taylor‐Robinson	14
5	Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes 2020 ·Journal of Viral Hepatitis ·Michael Ankcorn, Bengü Said, Dilys Morgan, Ahmed M. Elsharkawy, (unknown), Stephen Ryder, Talal Valliani, F. Gordon, Kushala Abeysekera, Deepak Suri, Stuart McPherson, Jack Galliford, Belinda Smith, Emanuela Pelosi, Sanjay Bansal, Claire Bethune, David Sheridan, (unknown), Richard S. Tedder, Samreen Ijaz, (unknown)	14
6	Acute myeloid leukaemia: an unusual cause of biliary strictures 2019 ·BMJ Case Reports ·(unknown), Hannah Hunter, Simon Jackson, David Sheridan	3
7	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease breakdown → 2019 ·Gastroenterology ·Peter Eddowes, M. Sasso, Michael Allison, Emmanuel Tsochatzis, Quentin M. Anstee, David Sheridan, Indra Neil Guha, Jeremy Cobbold, Jonathan J Deeks, Valérie Paradis, Pierre Bédossa, Philip N. Newsome	930
8	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey 2017 ·Frontline Gastroenterology ·David Sheridan, Guruprasad P. Aithal, William Alazawi, Michael Allison, Quentin M. Anstee, Jeremy Cobbold, Shahid A. Khan, Andrew Fowell, Stuart McPherson, Philip N. Newsome, Jude A. Oben, Jeremy Tomlinson, Emmanuel Tsochatzis	24
9	Hepatitis C virus and atherosclerosis: A legacy after virologic cure? 2016 ·Clinics and Research in Hepatology and Gastroenterology ·M.F. Bassendine, (unknown), Simon H. Bridge, Daniel J. Felmlee, David Sheridan, Chris J. Packard, R. Dermot G. Neely	15
10	PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism 2014 ·Journal of Hepatology ·Simon H. Bridge, David Sheridan, Daniel J. Felmlee, Mary M.E. Crossey, (unknown), Clare Lanyon, Geneviève Dubuc, Nabil G. Seidah, Jean Davignon, Howard C. Thomas, Simon D. Taylor‐Robinson, G. L. Toms, R. Dermot G. Neely, Margaret F. Bassendine	33
11	Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency 2014 ·Metabolic Brain Disease ·David Sheridan, Simon H. Bridge, Mary M.E. Crossey, Daniel J. Felmlee, H. C. Thomas, R. Dermot G. Neely, Simon D. Taylor‐Robinson, M.F. Bassendine	9
12	IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection 2014 ·Journal of Hepatology ·Mohammed Eslam, Reynold Leung, Manuel Romero‐Gómez, Alessandra Mangia, William L. Irving, David Sheridan, Ulrich Spengler, Lindsay Mollison, Wendy Cheng, Elisabetta Bugianesi, Duncan McLeod, Abed M. Zaitoun, (unknown), (unknown), Jacob Nattermann, Mark W. Douglas, David Booth, Jacob George, Golo Ahlenstiel	29
13	Lipids and HCV 2012 ·Seminars in Immunopathology ·Margaret F. Bassendine, David Sheridan, Simon H. Bridge, Daniel J. Felmlee, R. Dermot G. Neely	86
14	Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs) 2012 ·Clinics and Research in Hepatology and Gastroenterology ·David Sheridan, R. Dermot G. Neely, Margaret F. Bassendine	21
15	Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity 2012 ·Journal of Hepatology ·David Sheridan, Simon H. Bridge, Daniel J. Felmlee, Mary M.E. Crossey, Howard C. Thomas, Simon D. Taylor‐Robinson, G. L. Toms, R. Dermot G. Neely, Margaret F. Bassendine	29
16	The ‘interferon paradox’ as a predictor of non-response to anti-viral therapy: novel association with apolipoprotein E and hepatitis C virus (HCV) lipoviralparticles (LVP). 2011 ·Gut ·David Sheridan, Simon H. Bridge, Daniel J. Felmlee, Stephen T. Robinson, Howard Thomas, G. L. Toms, D. Neely, Margaret F. Bassendine	0
17	P50 Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic hepatitis C infection: evidence for genotype-specific modulation of lipid pathways 2011 ·Gut ·Simon H. Bridge, David Sheridan, Daniel J. Felmlee, Mary M.E. Crossey, Howard Thomas, Simon D. Taylor‐Robinson, G. L. Toms, D. Neely, Margaret F. Bassendine	1
18	Depression in chronic hepatitis C is associated with low apolipoprotein e levels 2011 ·Gut ·David Sheridan, Mary M.E. Crossey, Stephen T. Robinson, Simon H. Bridge, Daniel J. Felmlee, Howard Thomas, G. L. Toms, D. Neely, Margaret F. Bassendine	1
19	Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles 2010 ·Gastroenterology ·Daniel J. Felmlee, David Sheridan, Simon H. Bridge, Søren Nielsen, Ross W. Milne, Chris J. Packard, Muriel Caslake, John McLauchlan, G. L. Toms, R. Dermot G. Neely, Margaret F. Bassendine	55
20	IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy breakdown → 2009 ·Nature Genetics ·(unknown), Vijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel, Thomas Berg, Martin Weltman, Maria Lorena Abate, Margaret F. Bassendine, Ulrich Spengler, Gregory J. Dore, Elizabeth E. Powell, Stephen M. Riordan, David Sheridan, Antonina Smedile, Vincenzo Fragomeli, Tobias Müller, Melanie Bahlo, Graeme J. Stewart, David Booth, Jacob George	1460

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact